Storage and Transport: New USP Chapter for Investigational Drug Products

Recommendation
9 September 2025
Basel, Switzerland
Specifics in the Distribution of Medicinal Products
In the Pharmacopeial Forum 42(4) [Jun-Jul 2016], the General Chapters - Packaging and Distribution Expert Committee of the U.S. Pharmacopeial Concention (USP) proposed a new chapter as an addition to the Good Storage and Distribution Practices for Drug Products chapters [1079]. This new subchapter should focus on investigational drug products (IDPs; investigational medicinal products in Europe, IMPs).
In the introduction, USP acknowledges that IDPs differ from commercial products:
- Small quantities for many different sites
- Less stability data available especially for early phases of clinical trials
- Temperature excursions of a single container "may jeopardize the entire clinical trial outcome"
Another challenge are different distribution requirements for IDPs in various countries. Sponsors should be aware of this.
The key expectations specified in the proposed new chapter are:
- Storage in a safe and secured area at labelled storage conditions
- Segregation for IDPs not or not yet dispensed yet and for IDPs awaiting return to sponsor or contractor
- Site qualification audits need to be performed
- Anticipation and tracking of expiry or re-test extensions (according to different local regulatory requirements)
- Packaging qualifications should be the same as for commercially available drug products
- Consideration of important distribution risk factors (e.g. distance, time, temperature, handoffs, packaging)
- Confirmation that proper steps are taken to ensure IDP supply chain integrity (including checklists for patients)
- Unblinded IDPs should be quarantined
- Comparators should be shipped and stored according their (new) IDP labelling
The draft chapter also gives a detailed example for calculating a rating of shipment risk that can help to identify probability and impact of missteps in the supply chain.
The deadline for comments is September 30, 2016
After registration on the USP Pharmacopeial Forum website the complete drafts can be accessed.
Related GMP News
10.06.2025Stimuli Article Proposes Revision of USP Definition of Controlled Room Temperature (CRT)
10.06.2025New MHRA Blog Post: Supplying Medicines to Ships, Aircraft and Oil Platforms
10.06.2025Questions and Answers from the ECA Webinar "GDP Update 2025" - Part 3
10.06.2025Meet the GDPA Board Members at the GDP Forum in Barcelona
10.06.2025Swissmedic Technical Interpretation: What Counts as a Major Change in GDP?
10.06.2025MHRA informes about Validity Date of UK issued GDP Certificates